Senhwa Biosciences announces positive data from phase 1/expansion trial of Silmitasertib for basal cell carcinoma treatment: Taipei, Taiwan Thursday, April 3, 2025, 15:00 Hrs [IST ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced ...

Libtayo was originally marketed with Sanofi ... which trials showed brought a very positive 74% remission rate, and the FDA is due to respond by the end of July 2025. Given their previous ...

Libtayo could capture up to $1 billion in sales from the NSCLC category, according to analysts, although additional upside is possible if an ongoing combination study yields positive results.

His positive outlook is driven by the company ... Its marketed products include EYLEA, Dupixent, Libtayo, Kevzara, and others. On March 14, Evan Seigerman, an analyst from BMO Capital, maintained ...

Immuneering has entered a clinical supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Regeneron’s Libtayo for ... moves and positive trial data have ...

Immuneering has entered a clinical supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Regeneron’s Libtayo for non-small cell ... Immuneering’s strategic moves ...

Regulatory progress continues, with a positive CHMP recommendation for the ... Key products like EYLEA, Libtayo, and Dupixent propelled the company’s growth. Dupixent continues to be a major ...